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Background: Intensive speech-language therapy (SLT) can promote recovery from
chronic post-stroke aphasia, a major consequence of stroke. However, effect sizes of
intensive SLT are moderate, potentially reflecting a physiological limit of training-induced
progress. Transcranial direct current stimulation (tDCS) is an easy-to-use, well-tolerated
and low-cost approach that may enhance effectiveness of intensive SLT. In a recent
phase-II randomized controlled trial, 26 individuals with chronic post-stroke aphasia
received intensive SLT combined with anodal-tDCS of the left primary motor cortex
(M1), resulting in improved naming and proxy-rated communication ability, with
medium-to-large effect sizes.
Aims: The proposed protocol seeks to establish the incremental benefit from
anodal-tDCS of M1 in a phase-III randomized controlled trial with adequate power,
ecologically valid outcomes, and evidence-based SLT.
Methods: The planned study is a prospective randomized placebo-controlled (using
sham-tDCS), parallel-group, double-blind, multi-center, phase-III superiority trial. A
sample of 130 individuals with aphasia at least 6 months post-stroke will be recruited
in more than 18 in- and outpatient rehabilitation centers.
Outcomes: The primary outcome focuses on communication ability in chronic
post-stroke aphasia, as revealed by changes on the Amsterdam-Nijmegen Everyday
Language Test (A-scale; primary endpoint: 6-month follow-up; secondary endpoints:
immediately after treatment, and 12-month follow-up). Secondary outcomes include
measures assessing linguistic-executive skills, attention, memory, emotional well-being,
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quality of life, health economic costs, and adverse events (endpoints: 6-month follow-up,
immediately after treatment, and 12-month follow-up).
Discussion: Positive results will increase the quality of life for persons with aphasia
and their families while reducing societal costs. After trial completion, a workshop with
relevant stakeholders will ensure transfer into best-practice guidelines and successful
integration within clinical routine.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03930121.
Keywords: chronic post-stroke aphasia, intensive speech-language therapy, transcranial direct current
stimulation, rehabilitation, randomized controlled trial
INTRODUCTION
Cerebrovascular diseases are among the most common causes
of disability worldwide, and about one third of stroke survivors
initially suffer from communication disorders, including aphasia
(1). In up to 40% of these individuals, symptoms of aphasia
persist 6 months after stroke and rarely recover spontaneously
in the ensuing time (2). Critically, chronic post-stroke aphasia
affects vocational reintegration, social life, and emotional well-
being while placing major burdens on the healthcare system (3).
Meta-analyses concluded that intensive speech-language
therapy (SLT) can be effective even in the chronic stage of
symptoms (4). In a multi-center randomized controlled trial
(RCT), persons with chronic post-stroke aphasia were randomly
assigned to either 3 weeks of intensive SLT or a waiting period
prior to treatment (5). Verbal communication improved after
intensive SLT, but not after the waiting period, as assessed by
the Amsterdam-Nijmegen Everyday Language Test (ANELT)
(6). The study revealed an average increase of three points
on the ANELT (A-scale) immediately after intensive SLT, a
relative difference amounting to ∼10% (between-group effect:
Cohen’s d = 0.58).
Motivated by a lack of data identified in systematic reviews (7),
several proof-of-concept studies provide evidence suggesting that
transcranial direct current stimulation (tDCS) is an easy-to-use,
well-tolerated, and low-cost approach to boost the effectiveness of
SLT in chronic post-stroke aphasia (8). Most of these studies are
small-to-medium phase-II trials, with naming ability (9) or other
linguistic skills as primary outcomes, but no parameters reflecting
everyday life (7), or with individually determined stimulation
not feasible for standard application (9–11). Moreover, most of
the studies did not assess training effects over extended periods
of time.
Our group recently published the first prospective
randomized placebo-controlled (using sham-tDCS), parallel-
group, double-blind, single-center, phase-II superiority trial on
intensive naming therapy combined with anodal-tDCS of the left
primary motor cortex (M1), including a sample of 26 persons
Abbreviations: AAT, Aachen Aphasia Test; ANCOVA, analysis of covariance;
ANELT, Amsterdam-Nijmegen Everyday Language Test; M1, primary motor
cortex; RCT, randomized controlled trial; SLT, speech-language therapy; tDCS,
transcranial direct current stimulation.
with post-stroke aphasia, a 6-month follow-up, and outcomes
relevant to everyday life (12). Results indicated significantly
improved naming and proxy-rated communication ability
in both groups. However, treatment gains for trained items
were significantly better maintained in the anodal-tDCS group
at the 6-months follow-up (Cohen’s d = 1.19). Importantly,
progress in communication ability was significantly higher with
anodal-tDCS than with sham-tDCS at all endpoints (Cohen’s
d = 0.75–0.99).
In summary, preliminary data suggest that anodal-tDCS can
benefit naming and communication ability in chronic post-
stroke aphasia, with medium-to-large effect sizes and long-term
stability of treatment gains. To ensure transfer of the intervention
to best-practice guidelines and successful integration within
clinical routine, a phase-III RCT is needed with adequate power,
ecologically valid outcomes, and evidence-based SLT (5).
MATERIALS AND METHODS
Design
The planned study DC-TRAIN-APHASIA (transcranial direct
current stimulation to enhance training effectiveness in chronic
post-stroke aphasia) is a prospective randomized placebo-
controlled (using sham-tDCS), parallel-group, double-blind,
multi-center, phase-III superiority trial.
Patient Involvement and Ethics Approval
Patients, relatives, and their representatives were given the
opportunity to discuss the study protocol and utter concerns
not addressed in a draft proposed at the time. It was pointed
out that in- and exclusion criteria should reflect realistic
routine-healthcare conditions; we followed this advice, whenever
possible. The final protocol was approved by the Ethics
Review Board of the University Medicine Greifswald, Germany
(reference number: BB-013/18). Written informed consent will
be obtained from each participant. All study procedures are in
accordance with the Declaration of Helsinki in its current version
(for details, see www.wma.net).
Recruitment and Setting
Individuals with chronic post-stroke aphasia will be recruited
in more than 18 in- and outpatient rehabilitation centers
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throughout Germany (for an updated list of study sites, see
record on ClinicalTrials.gov; identifier: NCT03930121). A similar
network of rehabilitation centers proved to be time- and cost-
effective in a previous large-scale RCT with long-term follow-
ups (5).
In- and Exclusion Criteria
Inclusion criteria are: Left-hemisphere cortical or subcortical
stroke with first-ever aphasic symptoms; at least 6 months post-
onset of stroke; fluent or non-fluent aphasia, as determined
by the Aachen Aphasia Test (AAT) (13); moderate-to-severe
word finding difficulties (maximum of 60% correct items on
a computerized naming task before treatment); at least one
correct reaction on the first part of the AAT subscale Token
Test (ensuring basic comprehension skills); at least one point
on the communicative task of the AAT subscale Spontaneous
Speech (ensuring basic communication abilities); German as
first language; age range 18–70 years; and intact left-hemisphere
“hand knob” and underlying white matter (for placement of
anode), as well as intact right-hemisphere prefrontal cortex (for
placement of cathode), to rule out stimulation of lesioned areas,
as confirmed by magnetic resonance imaging (MRI) or computer
tomography (CT) scans.
Exclusion criteria are: Contraindications for tDCS (e.g.,
cardiac pacemaker, history of seizures, implanted metal inside
the head); more than one clinically apparent stroke with aphasic
symptoms, as documented by clinical records and MRI or
CT scans of the brain; other severe neurological diseases, as
assessed by an independent neurologist (e.g., epilepsy, brain
tumor, subdural hematoma); psychiatric conditions that may
impair effective communication, as evaluated by an independent
clinical psychologist or psychiatrist according to the DSM-5
system: current diagnosis of severe alcohol or substance use
disorder (at least six out of eleven symptoms), current major
depressive episode (at least five out of nine symptoms, among
them depressed mood or anhedonia), and current disorder from
the psychotic spectrum (at least two out of five symptoms,
among them delusions, hallucinations or disorganized speech)
(14); severe apraxia of speech, as revealed by Hierarchical Word
Lists (<20% phonetically and phonematically correct items) (15);
severe non-verbal cognitive deficits, as demonstrated by the
Corsi Block-Tapping Task (less than four correct items) (16);
severely impaired vision or hearing that prevents individuals
from engaging in intensive SLT based on clinical experience;
and changes in centrally active drugs within 2 weeks prior to
study inclusion.
Randomization
In addition to intensive SLT, participants will either receive
anodal-tDCS or sham-tDCS, depending on group assignment
(allocation ratio of 1:1). Groups will be stratified-randomized
according to age (<60 vs. ≥ 60 years), aphasia severity at
baseline (AAT t-score classification at screening: severe vs. mild-
to-moderate aphasic symptoms), and center (for details, see
Figure 1). Block randomization will be used (randomly varying
block sizes of 4 and 6).
Behavioral Treatment, Stimulation, and
Blinding
In the planned RCT, participants will receive intensive treatment
(5) consisting of computer-assisted naming therapy (12) and
face-to-face communicative-pragmatic therapy (17). Treatment
will be tailored to the participants’ individual needs. For naming
therapy, personally relevant items will be chosen in a baseline
screening to reflect individual language ability, a procedure
previously described and established in a phase-II RCT (12). For
communicative-pragmatic therapy, training tasks of individual
complexity will be identified in an extensive baseline screening
(18). These tasks will include a variety of situations known from
everyday life that require verbal and non-verbal skills in context
of social interaction (17). Treatment will be administered in two
daily sessions over a period of three consecutive weeks (2 h of
daily naming therapy; 30min of daily communicative-pragmatic
therapy; total weekly dosage: 12.5 h). During the entire 3-week
treatment period, participants will not attend any other form
of SLT.
Intensive SLT will be combined with tDCS using a battery-
driven device (DC-Stimulator Plus, NeuroConn, Ilmenau,
Germany). The anode (5 × 7 cm2) will be placed horizontally
over the left M1 representation of the hand (C3 of the 10–
20 international EEG system) (12, 19). A functionally inert
cathode (10 × 10 cm2) will be positioned over the right
supraorbital region. In the Intervention Group, participants will
receive 20min of excitatory anodal-tDCS of M1 administered
at the beginning of each session. In the Control Group, the
current will be ramped up and remain at 1mA only for 30 s
prior to ramping down. This sham-tDCS does not affect neural
activity, but ensures blinding of participants due to initial tingling
sensations on the scalp, and therefore is the comparator of
choice consistent with previous work (12, 19). Participants and
therapists will be blinded to group assignment by using the “study
mode” of the stimulator, a masked randomization procedure
determined by algorithms. The randomization sequence will be
encrypted and stored on a secure server. Crucially, participants
and therapists will be unaware of the group assignment
throughout the entire study. To further increase blinding
integrity, data evaluation will be performed by an independent
Endpoint Committee blinded to group assignment and time
of assessment.
Hypotheses
The primary hypothesis predicts that intensive SLT combined
with anodal-tDCS leads to better communication ability than
intensive SLT combined with sham-tDCS. Likewise, secondary
hypotheses predict favorable scores on secondary outcomes with
anodal-tDCS compared to sham-tDCS (for details, see Table 1).
Primary endpoint will be a 6-month follow-up; secondary
endpoints will be immediately after treatment, and a 12-month
follow-up. The 6-month follow-up as primary endpoint is
assumed to reflect the impact of symptom recovery on aspects
of everyday life most adequately and proved to be particularly
sensitive to the effect of anodal-tDCS in previous work (12). The
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FIGURE 1 | Trial flow. SLT, Speech-language therapy; tDCS, transcranial direct current stimulation; ANELT, Amsterdam-Nijmegen Everyday Language Test (A-scale).
12-month follow-up will help explore the long-term stability of
the expected results.
Primary Outcome
Communication ability in 10 everyday-life situations will
be evaluated by parallel versions of the ANELT (A-scale)
(6). ANELT has good psychometric properties, including
high test-retest reliability and sensitivity to treatment-induced
progress in chronic post-stroke aphasia (2, 5). Each testing
session will be videotaped and scored oﬄine by the external
Endpoint Committee.
Secondary Outcomes
Secondary endpoints include measures representing linguistic-
executive skills, attention, memory, emotional well-being, quality
of life, health economic costs, and adverse events (for details,
see Table 1).
Sample Size Estimates
We expect a between-group difference on the ANELT of at
least three points at the 6-month follow-up. An independent-
sample t-test with a two-sided significance level of 0.05
has a power of 80% to detect an average between-group
difference of 3.0 points (standard deviation: 5.8) at the 6-
month follow-up if data from 120 participants are analyzed,
according to calculations using nQuery with raw data from
previous work (12). Assuming a drop-out rate of 10%, 130
individuals will be recruited. Determining samples sizes with
t-tests is a conservative approach: the planned analysis of
covariance (ANCOVA) with (1–p2) × n participants has the
same power as a t-test with n participants, where p is
the variance deflation factor, calculated by the correlation
of baseline and follow-up measures (30). In the worst
case of p = 0, the resulting sample size corresponds to
a t-test.
Statistical Analyses
Focusing on the primary hypothesis, we will conduct an
ANCOVA with the 6-month follow-up ANELT scores as
dependent variable, with group assignment (anodal-tDCS or
sham-tDCS) as independent variable, and baseline ANELT
scores as covariate. Further covariates are the stratification
parameters specified above (i.e., age, aphasia severity at
baseline, and center). The trial outcome will be analyzed
on an “intention-to-treat” basis in the total group. In the
event of missing values, multiple imputation methods will be
applied, if appropriate. Regarding the secondary hypotheses,
data will be analyzed using standard statistical methods while
adjusting for possible confounders, including the stratification
parameters. As participants may differentially benefit from
anodal-tDCS of M1 depending on type of aphasia, exploratory
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TABLE 1 | Testing.
Study procedure Pre-
screening

















Study month 0 Week 1–3 1 6 12
Informed consent •
In- and exclusion criteria (chart-based) •
In- and exclusion criteria (study-specific) •
Demographics and medical history •
Prior and current treatment •
Vital signs •
Physical examination •
Magnetic resonance imaging •
Aachen Aphasia Test • •
Hierarchical Word Lists •
Corsi Block-Tapping Task •
Amsterdam Nijmegen Everyday Language Test • • • •




Scenario Test • •
Communicative Effectiveness Index • • • •
NeuroCogFX • •
Benton Visual Retention Test • •
SADQH-10 • • • •
SAQOL-39g • • • •
EQ-5D-5L and EQ-5D-VAS • • • •
Patient Resource Consumption Questionnaire • • •
Burden of informal caregivers • • • •
tDCS Safety Questionnaire • • • • •
Minimal Important Difference • • •
Selected linguistic functions, Aachen Aphasia Test (13); Apraxia of speech, Hierarchical Word Lists (14); Non-verbal working memory, Corsi Block-Tapping Task (15); Communication
ability (primary outcome), Amsterdam Nijmegen Everyday Language Test (A-scale; parallel versions used in counterbalanced order across participants) (6); Naming ability, personally
relevant trained and untrained items, consistent with previous work (12); (Non-)verbal communication, Communicative-Pragmatic Screening (18), Scenario Test (Nobis-Bosch et al.
in preparation), and Communicative Effectiveness Index (20); Attention and executive function, reaction-speed subscales from NeuroCogFX (21); Non-verbal episodic memory, Figure
Recognition Task from Benton Visual Retention Test (22); Mood, German version of the 10-item Stroke Aphasic Depression Questionnaire (SADQH-10) (23); Health-related quality of life,
SAQOL-39g (24); EQ-5D-5L and EQ-5D-VAS (25); Health economic evaluation: direct and indirect costs during the 12-month study period (determined by the self-developed Patient
Resource Consumption Questionnaire and based on common standardized unit cost assumptions), and Quality-Adjusted Life Years (derived from the EQ-5D-5L data) (26); Unpaid
support provided by family members or friends, Burden of informal caregivers (27); (Serious) adverse events, tDCS Safety Questionnaire (28); Subjective treatment-induced change, as
experienced by patients, therapists, and relatives, Minimal Important Difference (29).
subgroup analyses will determine response rates related to
individual syndromes.
Safety, Protocol, and Data Monitoring
Safety, protocol, and data monitoring will be conducted by
the Clinical Trials Coordination Center of the University
Medicine Greifswald. For constant tDCS applied over cortical
areas in awake humans, potential minor side effects are skin
irritation, initial phosphenes, headache, dizziness, and itching
under the electrode. Intensity, duration and frequency of tDCS
are within the limits suggested in current guidelines (31).
Number and type of adverse events will be diagnosed by a
study physician, reported to the Clinical Trial Management
within seven days, and classified using a standard questionnaire
(28). In addition, serious adverse events will be reported to an
independent Data Safety and Monitoring Board that will advise
whether to continue, modify or stop the treatment and decide
whether to unmask the group assignment. To ensure treatment
fidelity and participant compliance, all training sessions will
be audiotaped (naming therapy) or documented in written
form (communicative-pragmatic therapy). These materials will
be continuously evaluated by the Clinical Trial Management.
Moreover, the Data Safety and Monitoring Board will participate
in annual meetings with the Clinical Trial Management to ensure
adherence to the study protocol, including blinding integrity.
All primary and secondary outcomes will be scored by the
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external Endpoint Committee blinded to group assignment
and time of assessment. Access to the dataset and stimulator-
generated randomization sequence will be restricted to the
Clinical Trial Management and the Data Safety and Monitoring
Board. To protect individual privacy before, during and after
the trial, the dataset will be stored, analyzed and archived in a
pseudonymized manner.
DISCUSSION
The proposed protocol of a phase-III RCT aims to demonstrate
that intensive SLT combined with anodal-tDCS benefits verbal
communication and parameters related to activities of daily
living in chronic post-stroke aphasia. Previous phase-II RCT
data have shown that naming therapy combined with anodal-
tDCS improves performance of trained items and, to a smaller
degree, untrained items alongside proxy-rated communication
ability (12, 19). Progress in communication ability may have
a positive impact on associated factors, such as severity of
post-stroke depression. Thus, the current RCT considers the
overall outcome of intensive SLT on measures evaluating
linguistic-executive skills, attention, memory, emotional well-
being, quality of life, and health economic costs. In- and
exclusion criteria are kept liberal to allow generalization of the
expected results to realistic routine-healthcare conditions. The
age split of 60 years for randomization was chosen to control
for age-dependent cerebral changes, such as microangiopathy
or reduced neuroplasticity. Covering both utterance-centered
and communicative-pragmatic treatment strategies, the
selected SLT methods reflect best-practice guidelines in aphasia
rehabilitation (5).
There are two major reasons for stimulating M1 instead
of individually determined intact perilesional brain regions.
First, perilesional stimulation requires pre-treatment mapping
of preserved language-related neural activity. Such an approach
is time-consuming, expensive, and involves technical expertise
usually not available outside specialized research centers. Second,
the rationale for anodal-tDCS of M1 comes from neuroscience
evidence suggesting that the motor system is anatomically
and functionally linked with perisylvian eloquent areas (32–
34). Moreover, behavioral studies revealed that engaging the
primary motor cortex facilitates language processing in healthy
individuals (35–37) and in persons with aphasia (38–43).
Accordingly, phase-II RCT data confirm that anodal-tDCS of
M1 leads to elevated naming and communication performance
in chronic post-stroke aphasia (12) while increasing activity
and connectivity in the preserved language network (19).
Although the neural bases of recovery from aphasia are not
fully understood, anodal-tDCS of M1 may affect sensorimotor
coupling via pathways from posterior language regions (44)
or alter connectivity of motor and prefrontal areas relevant
to speech (45). Current spread may also change excitability
in premotor or prefrontal regions (46) and hence support
domain-general cognitive function, resulting in better language
performance across different aphasia subtypes, severity levels,
and lesion sites (47). To confirm the local influence of
anodal-tDCS on M1 and to investigate the underlying neural
mechanisms, an add-on study will focus on individualized
modeling of current flow in a subset of rehabilitation centers with
access to high-resolution MRI.
In conclusion, intensive SLT can relieve symptoms in chronic
post-stroke aphasia, but effect sizes are moderate (5). This
highlights the need to explore adjunct strategies, such as anodal-
tDCS, to enhance training effectiveness. Recently, we provided
phase-II RCT data indicating that intensive SLT combined with
anodal-tDCS of M1 benefits naming and communication ability
in chronic post-stroke aphasia, with medium-to-large effect sizes
(12). The present study seeks to establish anodal-tDCS of M1
by substantiating our previous findings in a phase-III RCT
with adequate power, ecologically valid outcomes, and evidence-
based SLT. After trial completion, a workshop with relevant
stakeholders will ensure transfer into best-practice guidelines and
successful integration within clinical routine.
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